SBRT of ventricular tachycardia using 4pi optimized trajectories.
4pi trajectories
SBRT
radiosurgery
ventricular tachycardia
Journal
Journal of applied clinical medical physics
ISSN: 1526-9914
Titre abrégé: J Appl Clin Med Phys
Pays: United States
ID NLM: 101089176
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
revised:
05
09
2021
received:
26
04
2021
accepted:
03
10
2021
pubmed:
23
10
2021
medline:
15
12
2021
entrez:
22
10
2021
Statut:
ppublish
Résumé
To investigate the possible advantages of using 4pi-optimized arc trajectories in stereotactic body radiation therapy of ventricular tachycardia (VT-SBRT) to minimize exposure of healthy tissues. Thorax computed tomography (CT) data for 15 patients were used for contouring organs at risk (OARs) and defining realistic planning target volumes (PTVs). A conventional trajectory plan, defined as two full coplanar arcs was compared to an optimized-trajectory plan provided by a 4pi algorithm that penalizes geometric overlap of PTV and OARs in the beam's-eye-view. A single fraction of 25 Gy was prescribed to the PTV in both plans and a comparison of dose sparing to OARs was performed based on comparisons of maximum, mean, and median dose. A significant average reduction in maximum dose was observed for esophagus (18%), spinal cord (26%), and trachea (22%) when using 4pi-optimized trajectories. Mean doses were also found to decrease for esophagus (19%), spinal cord (33%), skin (18%), liver (59%), lungs (19%), trachea (43%), aorta (11%), inferior vena cava (25%), superior vena cava (33%), and pulmonary trunk (26%). A median dose reduction was observed for esophagus (40%), spinal cord (48%), skin (36%), liver (72%), lungs (41%), stomach (45%), trachea (53%), aorta (45%), superior vena cava (38%), pulmonary veins (32%), and pulmonary trunk (39%). No significant difference was observed for maximum dose (p = 0.650) and homogeneity index (p = 0.156) for the PTV. Average values of conformity number were 0.86 ± 0.05 and 0.77 ± 0.09 for the conventional and 4pi optimized plans respectively. 4pi optimized trajectories provided significant reduction to mean and median doses to cardiac structures close to the target but did not decrease maximum dose. Significant improvement in maximum, mean and median doses for noncardiac OARs makes 4pi optimized trajectories a suitable delivery technique for treating VT.
Identifiants
pubmed: 34679247
doi: 10.1002/acm2.13454
pmc: PMC8664144
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
72-86Informations de copyright
© 2021 The Authors. Journal of Applied Clinical Medical Physics published by Wiley Periodicals, LLC on behalf of The American Association of Physicists in Medicine.
Références
J Am Coll Cardiol. 2004 Dec 7;44(11):2166-72
pubmed: 15582314
J Digit Imaging. 2013 Dec;26(6):1045-57
pubmed: 23884657
Cureus. 2016 Jul 15;8(7):e694
pubmed: 27570715
J Cardiovasc Electrophysiol. 2010 Jan;21(1):47-53
pubmed: 19656251
J Am Coll Cardiol. 2000 Jun;35(7):1905-14
pubmed: 10841242
Eur J Cancer. 2017 Nov;85:106-113
pubmed: 28898766
Heart Rhythm. 2010 Jun;7(6):802-10
pubmed: 20156591
Arrhythm Electrophysiol Rev. 2016 Aug;5(2):117-21
pubmed: 27617090
Rep Pract Oncol Radiother. 2014 Nov 18;20(2):99-103
pubmed: 25859398
N Engl J Med. 2017 Dec 14;377(24):2325-2336
pubmed: 29236642
Int J Radiat Oncol Biol Phys. 2016 Mar 1;94(3):638
pubmed: 26867895
Phys Med Biol. 2018 Jun 13;63(12):125013
pubmed: 29786614
Pract Radiat Oncol. 2014 Mar-Apr;4(2):76-81
pubmed: 24890347
Heart Rhythm. 2018 Jan;15(1):48-55
pubmed: 28843418
Phys Med Biol. 2013 Nov 21;58(22):8163-77
pubmed: 24200876
Int J Radiat Oncol Biol Phys. 2019 Aug 1;104(5):1114-1123
pubmed: 31002942
Med Clin North Am. 2019 Sep;103(5):881-895
pubmed: 31378332
Heart Rhythm. 2021 Aug;18(8):1336-1343
pubmed: 33892202
Front Cardiovasc Med. 2018 Jul 09;5:83
pubmed: 30038908
Int J Cardiol. 2018 Sep 15;267:107-113
pubmed: 29655948
J Am Coll Cardiol. 2016 Feb 16;67(6):674-683
pubmed: 26868693
Med Phys. 2015 May;42(5):2317-25
pubmed: 25979026
Europace. 2019 Jul 1;21(7):1088-1095
pubmed: 31121018
J Arrhythm. 2020 Jan 03;36(1):1-58
pubmed: 32071620
PLoS One. 2015 Dec 11;10(12):e0144282
pubmed: 26657513
Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):962-7
pubmed: 16458781
Circulation. 2008 Jan 29;117(4):462-9
pubmed: 18172038
Heart Rhythm. 2020 Aug;17(8):1381-1392
pubmed: 32205299
J Appl Clin Med Phys. 2013 Jan 07;14(1):4035
pubmed: 23318391
Int J Radiat Oncol Biol Phys. 2011 Jul 15;80(4):1238-47
pubmed: 21377811
Med Phys. 2020 Feb;47(2):307-316
pubmed: 31659750
J Appl Clin Med Phys. 2021 Dec;22(12):72-86
pubmed: 34679247
J Appl Clin Med Phys. 2020 Nov;21(11):195-204
pubmed: 33073454
Circulation. 2008 Dec 16;118(25):2773-82
pubmed: 19064682
Int J Radiat Oncol Biol Phys. 1997 Feb 1;37(3):731-6
pubmed: 9112473
Int J Radiat Oncol Biol Phys. 2003 Jun 1;56(2):573-85
pubmed: 12738335
Med Phys. 2010 Aug;37(8):4078-101
pubmed: 20879569
Circ Arrhythm Electrophysiol. 2015 Jun;8(3):748-50
pubmed: 26082532
Int J Radiat Oncol Biol Phys. 2021 Mar 1;109(3):783-800
pubmed: 33160007
Clin Res Cardiol. 2020 Nov;109(11):1319-1332
pubmed: 32306083
J Am Heart Assoc. 2013 May 31;2(3):e000072
pubmed: 23727700
J Am Coll Cardiol. 2017 May 2;69(17):2105-2115
pubmed: 28449770
Eur Heart J. 2000 Dec;21(24):2071-8
pubmed: 11102258